ArticleBMC cancer2019
Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 74 citations in OpenAlex.
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- SLC2A3 Expression is Differentially Associated with Postoperative Recurrence, Complications, and Liver Metastasis in Colorectal Cancer.Cancer management and research · 2026Article
- Transcriptional Activity of Genes Related to the Biotransformation Process in the Development of Colorectal Cancer.International journal of molecular sciences · 2025Article
- Development of a prognostic prediction model based on damage-associated molecular pattern for colorectal cancer applying bulk RNA-seq analysis.Scientific reports · 2025Article
- Development and validation of a prognostic model based on disulfidptosis-related ferroptosis genes:Translational cancer research · 2025Article
- New Insights into Colorectal Cancer through the Lens of Precision Oncology and Personalized Medicine: Multi-Omics Helps Aging of Predisposed People.Current aging science · 2025Review
- Towards precision oncology discovery: four less known genes and their unknown interactions as highest-performed biomarkers for colorectal cancer.NPJ precision oncology · 2024Article
- Predicting Survival Among Colorectal Cancer Patients: Development and Validation of Polygenic Survival Score.Clinical and experimental gastroenterology · 2024Article
- Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.Channels (Austin, Tex.) · 2023Article
- Correlations between class I glucose transporter expression patterns and clinical outcomes in non-small cell lung cancer.Thoracic cancer · 2023Article
- Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.International journal of molecular sciences · 2023Article
- Establishment and validation of a ferroptosis-related signature predicting prognosis and immunotherapy effect in colon cancer.Frontiers in oncology · 2023Article
- Exploring the correlation of glycolysis-related chondroitin polymerizing factor (American journal of cancer research · 2023Article
- Identification of Gene Signature-Related Oxidative Stress for Predicting Prognosis of Colorectal Cancer.Oxidative medicine and cellular longevity · 2023Article
- Natural killer cell-related prognosis signature predicts immune response in colon cancer patients.Frontiers in pharmacology · 2023Article
- Article
- Angiopoietin-like 4 promotes glucose metabolism by regulating glucose transporter expression in colorectal cancer.Journal of cancer research and clinical oncology · 2022Article
- Review
- Identification of molecular mechanism and key biomarkers in membranous nephropathy by bioinformatics analysis.American journal of translational research · 2022Article
- Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundUpregulation of SLC2A genes that encode glucose transporter (GLUT) protein is associated with poor prognosis in many cancers. In colorectal cancer, studies reporting the association between overexpression of GLUT and poor clinical outcomes were flawed by small sample sizes or subjective interpretation of immunohistochemical staining. Here, we analyzed mRNA expressions in all 14 SLC2A genes and evaluated the association with prognosis in colorectal cancer using data from the Cancer Genome Atlas (TCGA) database.
methodsIn the present study, we analyzed the expression of SLC2A genes in colorectal cancer and their association with prognosis using data obtained from the TCGA for the discovery sample, and a dataset from the Gene Expression Omnibus for the validation sample.
resultsSLC2A3 was significantly associated with overall survival (OS) and disease-free survival (DFS) in both the discovery sample (345 patients) and validation sample (501 patients). High SLC2A3 expression resulted in shorter OS and DFS. In multivariate analyses, high SLC2A3 levels predicted unfavorable OS (adjusted HR 1.95, 95% CI 1.22-3.11; P = 0.005) and were associated with poor DFS (adjusted HR 1.85, 95% CI 1.10-3.12; P = 0.02). Similar results were found in the discovery set.
conclusionUpregulation of the SLC2A3 genes is associated with decreased OS and DFS in colorectal cancer patients. Therefore, assessment of SLC2A3 gene expression may useful for predicting prognosis in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.